Taizhou, China —Space Peptides (Taizhou) Pharmaceutical Co., Ltd. has announced that its semaglutide active pharmaceutical ingredient (API) has successfully completed a Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under filing number 044181. This is the company’s first API to achieve an overseas DMF filing, marking a key milestone in its internationalization and securing its products to enter the world’s mainstream regulated markets.
The completion of this filing underscores Space Peptides (Taizhou)’s core strengths in API research and development, manufacturing, and quality control. It is a strategic achievement of the company’s commitment to aligning with international regulatory standards and pursuing a path of high-quality development.
Semaglutide: From Glucose Control and Weight Loss to Multiple indications.
Semaglutide is a novel, long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) used primarily to treat type 2 diabetes and obesity. Beyond its approved indications for blood-glucose control and weight management, the drug offers multiple additional benefits, including cardiovascular and cerebrovascular protection, renal protection, and improvement of insulin resistance in the liver and brain. It is also a potential treatment option for non-alcoholic fatty liver disease and neurodegenerative disorders.
First approved in the United States in December 2017 and in China in April 2021, semaglutide is now widely used across more than 50 countries and regions in the Americas, Europe, and Asia.
In 2025, semaglutide is rapidly evolving from a single glucose-lowering and weight-loss therapy into a treatment offering protection across cardiac, renal, and metabolic systems. Key milestones include confirmation of cardiovascular benefit for the oral formulation (the SOUL trial), expansion of its indication to non-alcoholic steatohepatitis (MASH), the launch of the world’s first oral GLP-1 weight-loss drug, and formal approval of a chronic kidney disease (CKD) indication.
Deepening Its Presence in the Global Peptide API Market
An FDA DMF filing is one of the important qualifications for global API companies seeking entry into regulated markets. The successful DMF filing of Space Peptides (Taizhou) semaglutide API demonstrates that the company has established a mature system for API process development, quality control, and large-scale production.
Drawing on core technical advantages accumulated in both solid-phase and liquid-phase synthesis, together with its large-scale manufacturing facilities, Space Peptides (Taizhou)’s will continue to advance API registration across multiple global markets and actively expand peptide API collaborations with overseas customers. The company is committed to providing high-quality, competitive peptide APIs to clients worldwide and to enabling the broader application of peptide-based medicines.
About Space Peptides (Taizhou)
Commissioned at the end of 2024, the company’s facility is located in the Taixing Economic Development Zone, Jiangsu Province — China’s third-ranked chemical industrial park. The site covers 80,000 square meters and represents a total investment of more than RMB 1 billion, with convenient logistics just a two-hour drive from Shanghai. Home to a world-leading, intelligent CRDMO smart factory, Space Peptides (Taizhou) focuses on peptides, oligonucleotides, and synthetic conjugate drugs, delivering end-to-end, full-chain CRDMO solutions for customers — from new-drug discovery and development through GMP manufacturing to global registration and commercialization.